All In Biotech

Drug Trial Radar · NCT03403712

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (Akynzeo®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Initial and Repeated Cycles of Anthracycline-cyclophosphamide (AC) Chemotherapy in Women With Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jun 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 404 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

404

Actual

Start

Mar 16, 2018

Primary completion

Sep 19, 2018

Study completion Sep 19, 2018

Sponsor

Lead sponsor
Helsinn Healthcare SAIndustry
Sponsor type
Industry
Collaborators
Emerald Clinical Inc.; The Physicians' Services Incorporated Foundation
First posted
Jan 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion \[test\] versus oral netupitant/palonosetron (300 mg/0.5 mg) combination \[control\]; each administered with oral dexamethasone prior to initial and repeated cycles of AC chemotherapy in female breast cancer patients.

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

  • fosnetupitant/ palonosetronDrug

    intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination

  • netupitant/palonosetronDrug

    oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination

  • dexamethasoneDrug

    Oral dexamethasone (12 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent AEs at Cycle 1Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Number of Participants With Treatment-emergent AEs All CyclesTime frame: At the end of Cycle 4 (each cycle is 21 days)
  3. Number of Participants With Severe (i.e., CTCAE Grade ≥3) TEAEs Reported for ≥2% of Patients in Either Treatment Group and Overall Throughout the StudyTime frame: At the end of Cycle 4 (each cycle is 21 days)
  4. Number of Participants With Study-Drug-Related TEAEs Reported for ≥2% of Patients in Either Treatment Group Throughout the StudyTime frame: At the end of Cycle 4 (each cycle is 21 days)

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • The Oncology Inst. Of Hope and Innovation

    Tucson, Arizona

  • Carti Cancer Center

    Little Rock, Arkansas

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • CBCC Global Research, INC at Comprehensive Blood and Cancer Center

    Bakersfield, California

  • The Oncology Tnstitute of Hope and Innovation

    Corona, California

  • Uptimum Medical Group Inc.

    Inglewood, California

  • The Oncology Institute of Hope and Innnovation

    Long Beach, California

  • Hao Wei Zhang M.D.

    Los Angeles, California

  • Emad Ibrahim, MD, INC.

    Redlands, California

  • Watson Clinic LLP

    Lakeland, Florida

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • University Cancer & Blood Center, LLC

    Athens, Georgia

  • Cancer Center of !\!Iiddle Georgia

    Dublin, Georgia

  • Harbin Clinic

    Rome, Georgia

  • Summit Cancer Care

    Savannah, Georgia

  • Edward H. Kaplan MD & Associates

    Skokie, Illinois

  • Presence Infusion Care - Skokie

    Skokie, Illinois

  • Fort Wayne Medical Oncology and Hematology, Inc.

    Fort Wayne, Indiana

  • TU Health Arnett Cancer Center

    Lafayette, Indiana

  • Baptist Health Cancer Center

    New Albany, Indiana

  • Cotton O'Neil Clinical Res. Ctr., Hematology & Oncology

    Topeka, Kansas

  • Cancer Center of Kansas

    Wichita, Kansas

  • Ashland-Bellefonte Cancer Center

    Ashland, Kentucky

  • CHRISTUS Cancer Treatment Center

    Shreveport, Louisiana

  • Mercy Medical Center, Medical Oncology and Hematology

    Baltimore, Maryland

  • Hattiesburg Clinic Hematology Oncology

    Hattiesburg, Mississippi

  • Cornell-Beshore Cancer Institute

    Joplin, Missouri

  • Cox Mcdical ·Centers

    Springfield, Missouri

  • Trinitas Cancer Center

    Elizabeth, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Mid Ohio Oncology/Hematology Inc. DBA The Mark H. Zangmeister Center

    Columbus, Ohio

  • Toledo Clinic Cancer Center - Toledo

    Toledo, Ohio

  • Monongahela Valley Hospital

    Monongahela, Pennsylvania

  • Carolina Blood and Cancer Care Associates, P.A.

    Rock Hill, South Carolina

  • The West Clinic, PC dba West Cancer Center

    Germantown, Tennessee

  • Cheyenne Regional Medical Center

    Cheyenne, Wyoming

  • JSC Saint Nikolozi Surgery and Oncological Centre

    Kutaisi, Georgia

  • LTD Institute of Clinical Oncology

    Tbilisi, Georgia

  • LTD Tbilisi Oncology Dispensary

    Tbilisi, Georgia

  • LTD S.Khechinashvili University Hospital

    Tbilisi, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.